Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service DBS & VNS cases in Iowa: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 17% on average (103 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 181 | 24% |
| 2020 | 2 | 136 | 27% |
| 2021 | 3 | 198 | 30% |
| 2022 | 3 | 118 | 34% |
| 2023 | 1 | 121 | 38% |
| 2024 | 1 | 123 | 40% |
| 2025 from claims | – | 190 154–223 | 41% |
| 2026 forecast | – | 195 153–245 | 40% |
| 2027 forecast | – | 197 146–260 | 40% |
| 2028 forecast | – | 198 140–274 | 41% |
| 2029 forecast | – | 200 136–286 | 41% |
| 2030 forecast | – | 201 132–299 | 42% |
Deep brain and vagus nerve stimulator implants. Professional codes (what the surgeon bills): CPT 61863, 61867, 61885, 61886, 64568; the hospital bills MS-DRG 040, 041, 042.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Iowa; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 21% inpatient hospital, 79% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 9 | 430−6.8%/yr | −6.8%/yr | 0.4 | 0% | 580 in 2030+5.2%/yr |
| Minnesota | 3 | 324−2.1%/yr | −2.1%/yr | 0.7 | 0% | 460 in 2030+6.1%/yr |
| Kansas | 3 | 294+5.3%/yr | +5.3%/yr | 0.7 | 0% | 570 in 2030+12%/yr |
| Illinois | 4 | 294−8.4%/yr | −8.4%/yr | 0.2 | 0% | 330 in 2030+2.2%/yr |
| Missouri | 3 | 276−9.1%/yr | −9.1%/yr | 0.4 | 0% | 290 in 2030+0.5%/yr |
| Michigan | 2 | 246−8.8%/yr | −8.8%/yr | 0.3 | 0% | 130 in 2030−10%/yr |
| Indiana | 2 | 163−10%/yr | −10%/yr | 0.2 | 0% | 320 in 2030+12%/yr |
| Wisconsin | 3 | 158−3.1%/yr | −3.1%/yr | 0.3 | 0% | 140 in 2030−2.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Aneurysm & intracranial embolization | 5 | 166+11%/yr | +11%/yr | 0.40.9× | 0% | 360 in 2030+14%/yr |
| Stroke thrombectomy | 8 | 149+0.7%/yr | +0.7%/yr | 0.30.8× | 0% | 240 in 2030+8%/yr |
DBS & VNS in every state, and its device makers · Every procedure market in Iowa · Every state · Compare with Ohio
Johnson & Johnson MedTech leads with 69% of company spending on these surgeons in 2025, +7 pts on 2024.
In 2025, 4 companies reported engagement with Iowa’s surgeons worth $50K in consulting, speaking, meals and travel tied to these products, about $50K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 56 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.